Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 126

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 126
---
 the foreseeable future. To meet future capital needs, we would need to raise additional capital through equity or debt financing or other strategic transactions. However, any such financing may not be on favorable terms or even available to us. Our failure to obtain sufficient funds on commercially acceptable terms when needed would have a material adverse effect on our business, results of operations and financial condition. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses could prove to be significantly higher than we currently anticipate. Our future capital requirements will depend on many factors, including, but not limited to:

| ● | the progress and costs of our research and development 
 activities;                                            |

| ● | the costs of development and expansion of our operational 
 infrastructure;                                           |

| ● | our ability, or that of our collaborators, to achieve                                                
 development milestones and other events or developments under potential future licensing agreements; |

| ● | the amount of revenues and contributions we receive                                                                     
 under future licensing, collaboration, development and commercialization arrangements with respect to our technologies; |

| ● | the costs of filing, prosecuting, enforcing and                 
 defending patent claims and other intellectual property rights; |

| ● | the costs of contracting with third parties to provide                                                                             
 sales and marketing capabilities for us or establishing such capabilities ourselves, once our technologies are developed and ready 
 for commercialization;                                                                                                             |

| ● | the costs of acquiring or undertaking development                    
 and commercialization efforts for any future products or technology; |

| ● | the magnitude of our                     
 general and administrative expenses; and |

| ● | any additional costs that we may incur under future                                   
 in- and out-licensing arrangements relating to our technologies and futures products. |

Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through capital raising or by out-licensing and/or co-developing applications of one or more of our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available on favorable terms, or at all, we may be required to delay, reduce the scope of or eliminate research or development efforts or plans for commercialization with respect to our technologies and make necessary change to our operations to reduce the level of our expenditures in line